Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07741981). This is a study registration, not published results. Lead sponsor: Centre Hospitalier St Anne. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 700 participants (ESTIMATED). Conditions: Schizophrenia, Treatment Resistant Depression (TRD), Bipolar Disorder (BD), Catatonia, Obsessive Compulsive Disorder (OCD). Interventions: BIOLOGICAL: Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales. Primary outcome measures: Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) , Up to 10 weeks; Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) , Up to 10 weeks; Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) , Up to 10 weeks; Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) , Up to 10 weeks; Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) , Up to 10 weeks; Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks; Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). , Up to 10 weeks. Brief summary: The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.